Sign Out
Palivizumab is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease.
Children born at 35 weeks of gestation or less and less than 6 months of age at the onset of the RSV season.
Children less than 2 years of age and requiring treatment for bronchopulmonary dysplasia within the last 6 months.
Children less than 2 years of age and with haemodynamically significant congenital heart disease.
